Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lascufloxacin Switch Therapy for Community-Acquired Pneumonia
jRCTs071230001Completed
- Sponsor
- Kyorin Pharmaceutical
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lascufloxacin in community-acquired pneumonia (CAP), sponsored by Kyorin Pharmaceutical. Started May 2023; status: completed.
02
Drugs
lascufloxacin
03
Conditions
community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on jRCTs071230001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071230001.